News >

Polatuzumab Vedotin Approved in Europe for Relapsed/Refractory DLBCL

Gina Columbus @ginacolumbusonc
Published: Wednesday, Jan 22, 2020

Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development of Genentech (Roche)

Levi Garraway, MD, PhD

The European Commission has granted a conditional marketing authorization to polatuzumab vedotin (Polivy) in combination with bendamustine and rituximab (Rituxan; BR) for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for hematopoietic stem cell transplant.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication